Sonnet BioTherapeutics SONN 深 滬
已收盤 12-02 16:00:00 美东时间
1.26
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 1.26
- 總市值 398.89万
- 52周最高 19.30
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.08
- 委 比 0.00%
- 總股本 316.58万
- 歷史最高 329609.28
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.08
- 每 手 1
- 風險率 1.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sonnet BioTherapeutics Stockholders Approve Business Combination With Hyperliquid Strategies And Rorschach I
Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) ("Sonnet" or the "Company") today announced that its stockholders approved, among other things, the proposed business combination with Hyperliquid Strategies Inc
12-02 22:23
Catalyst Watch: Alibaba earnings, AI anxiety, airline M&A, and a Burry teaser
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - November ...
11-22 04:00
Sonnet BioTherapeutics Adjourns Meeting for Business Combination
Sonnet BioTherapeutics Holdings ( ($SONN) ) has shared an update. On November 1...
11-18 22:48
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
Sonnet BioTherapeutics Holdings announced it has adjourned its special stockholder meeting to allow additional time for voting on its proposed business combination with Hyperliquid Strategies Inc (HSI) and Rorschach I LLC. Over 95% of votes cast so far support the transaction. The Company's Board remains confident the proposals are in shareholders' best interest. HSI's shares have been approved for Nasdaq listing. The adjourned meeting will be he...
11-18 14:00
Sonnet BioTherapeutics Collaborates With Spanios On Non-Clinical Study Using NAM-Based PDT Platforms That Emulate TME Ex Vivo To Evaluate Effect Of SON-1010 In Soft Tissue Sarcoma
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patient-derived tumoroid (PDT) platforms that emulate the tumor
10-15 22:05
Sonnet to Present at the MedInvest Biotech & Pharma Conference
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announces that Interim CEO Raghu Rao will present at the MedInvest Biotech & Pharma Conference on September 25, 2025, at 9:40 AM PT in Palo Alto, California. A live webcast of the presentation will be available on the company's Events page under its Investors section. Sonnet specializes in developing immunotherapeutic drugs targeting the tumor microenvironment using its proprietary FHAB platform...
09-19 13:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock increased by 353.1% to $3.38 during Mond...
09-15 20:10
Why Check-Cap Shares Are Trading Higher By 183%; Here Are 20 Stocks Moving Premarket
Shares of Check-Cap Ltd. (NASDAQ:CHEK) rose sharply in pre-market trading. MBod...
09-15 17:45
Sonnet BioTherapeutics Q3 EPS $(0.95) Misses $(0.49) Estimate
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.49) by 93.88 percent. This is a 83.04 percent increase over losses of $(5.60) per
08-14 15:41
Sonnet Releases Virtual Investor "What This Means" Segment
Sonnet BioTherapeutics announced the expansion of its SB221 clinical trial for platinum-resistant ovarian cancer (PROC). The expansion group, using the highest maintenance dose (E6 dose of 1200 ng/kg), has completed enrollment. Two out of three patients in the E6 dose escalation cohort showed partial responses, allowing further safety study in a larger population. Preliminary efficacy results are expected later this year. An E7 cohort with a main...
08-11 13:15
